1. |
贺争鸣, 邢瑞昌, 方喜业, 等. 论实验动物福利、动物实验与动物实验替代方法. 实验动物科学与管理杂志, 2005, 22(1):61-64.
|
2. |
Roberts I, Kwan I, Evans P, et al. Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ, 2002,.
|
3. |
(7335):474-476.
|
4. |
Kilkenny C, Parsons N, Kadyszewski E, et al. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals. PLoS ONE, 2009, 4(11):e7824.
|
5. |
Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA, 1996, 276(8):637-639.
|
6. |
Kilenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting:The ARRIVE guidelines for reporting animal research. PLoS Biol, 2010, 8(6):e1000412.
|
7. |
Hooijmans CR, Leenaars M, Ritskes-Hoitinga M, et al. A gold Standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim, 2010, 38(2):167-182.
|
8. |
National Research Council (US) Institute for Laboratory Animal Research. Guidance for the Description of Animal Research in Scientific Publications,Washington (DC):National Academies Press (US), 2011.
|
9. |
Vesterinen HM, Egan K, Deister A, et al. Systematic survey of the design, statistical analysis, and reporting of studies published in the.
|
10. |
volume of the Journal of Cerebral Blood Flow and Metabolism. J Cereb Blood Flow Metab, 2011, 31(4):1064-1072.
|
11. |
Lamontagne F, Briel M, Duffett M, et al. Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis. Crit Care Med, 2010, 38(12):2401-2408.
|
12. |
Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early forbenefit:a systematic review. JAMA, 2005, 294(17):2203-2209.
|
13. |
Agerstrand M, Kuster A, Bachmann J, et al. Reporting and evaluation criteria as means towards a transparent use of ecotoxicity data for environmental risk assessment of pharmaceuticals. Environ Pollut, 2011, 159(10):2487-2492.
|
14. |
Conrad JW Jr, Becker RA. Enhancing credibility of chemical safety studies:emerging consensus on key assessment criteria. Environ Health Perspect, 2010, 119:757-764.
|
15. |
Verhagen H, Aruoma OI, van Delft JH, et al. The 10 basic requirements for a scientific paper reporting antioxidant, antimutagenic or anticarcinogenic potential of test substances in in vitro experiments and animal studies in vivo. Food Chem Toxicol, 2003, 41(5):603-610.
|
16. |
Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J, 2003, 43(4):244-258.
|
17. |
Altman DG, Gore SM, Gardner MJ, et al. Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed), 1983, 286(6376):1489-1493.
|
18. |
Festing MF. Guidelines for the design and statistical analysis of experiments in papers submitted to ATLA. Altern Lab Anim, 2001, 29(4):427-446.
|
19. |
Festing MF, van Zutphen LM. Guidelines for reviewing manuscripts on studies involving live animals. Synopsis of the workship. In:Animal Alternatives, Welfare and Ethics. Amsterdam:Elsevier, 1997:405-410.
|
20. |
Johnson PD, Besselsen DG. Practical aspects of experimental design in animal research. ILAR J, 2002, 43(4):202-206.
|
21. |
de Aguilar-Nascimento JE. Fundamental steps in experi-mental design for animal studies. Acta Cir Bras, 2005, 20(1):2-8.
|
22. |
Festing MF. Principles:the need for better experimental design. Trends Pharmacol Sci, 2003, 24(7):341-345.
|
23. |
Hooijmans CR, Rovers MM, de Vries RB, et al. SYRCLE's risk of bias tool for animal studies. BMC Medical Research Methodology, 2014, 14:43.
|
24. |
Minnerup J, Wersching H, Diederich K, et al. Methodological quality of preclinical stroke studies is not required for pub-lication in high-impact journals. J Cereb Blood Flow Metab, 2010, 30(9):1619-1624.
|
25. |
van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med, 2010, 7(3):e1000245.
|
26. |
Macleod MR, Fisher M, O'Collins V, et al. Good Laboratory Practice:preventing introduction of bias at the bench. Stroke, 2009, 40(3):e50-52.
|
27. |
Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke, 2009, 40(6):2244-2250.
|
28. |
Sena E, vander Worp HB, Howells D, et al. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci, 2007, 30(9):433-439.
|
29. |
Macleod MR, O'Collins T, Howells DW, et al. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke, 2004, 35(5):1203-1208.
|
30. |
Horn J, de Haan RJ, Vermeulen M, et al. Nimodipine in animal model experiments of focal cerebral ischemia:a systematic review. Stroke, 2001, 32(10):2433-2438.
|
31. |
Jonas S, Ayigari V, Viera D, et al. Neuroprotection against cerebral ischemia. A review of animal studies and correlation with human trial results. Ann NY Acad Sci, 1999, 890:2-3.
|
32. |
van der Worp HB, de Haan P, Morrema E, et al. Methodological quality of animal studies on neuroprotection in focal cerebral ischemia. J Neurol, 2005, 252(9):1108-1114.
|
33. |
Hsu CY. Criteria for valid preclinical trials using animal stroke models. Stroke, 1993, 24(5):633-636.
|
34. |
Maria Philip, Michael Benatar, Marc Fisher, et al. Methodological quality of animal studies of neuroprotective agents currently in phase ii/iii acute ischemic stroke trials. Stroke. 2009, 40(2):577-581.
|
35. |
Vesterinen HM, Sena ES, ffrench-Constant C, et al. Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler, 2010, 16(9):1044-1055.
|
36. |
Rice AS, Cimino-Brown D, Eisenach JC, et al. Animal models and the prediction of efficacy in clinical trials of analgesic drugs:a critical appraisal and call for uniform reporting standards. Pain, 2008, 139(2009):243-247.
|
37. |
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary? Control Clin Trials, 1996, 17(1):1-12.
|
38. |
Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis:the effect of ovariectomy and estrogen treatment:a systematic approach. Osteoarthritis Cartilage, 2008, 16(5):533-541.
|
39. |
Unger EF. All is not well in the world of translational research. Journal of the American College of Cardiology, 2007, 50(8):738-740.
|
40. |
Marshall JC, Deitch E, Moldawer LL, et al. Preclinical models of shock and sepsis:what can they tell us? Shock, 2005, 24(Suppl 1):1-6.
|
41. |
Bebarta V, Luyten D, Heard K. Emergency medicine animal research:does use of randomization and blinding affect the results? Acad Emerg Med, 2003, 10(6):684-687.
|
42. |
Lucas C, Criens-Poublon LJ, Cockrell CT, et al. Wound healing in cell studies and animal model experiments by low level laser therapy were clinical studies justified? A systematic review. Lasers Med Sci, 2002, 17(2):110-134.
|
43. |
Durda JL, Preziosi DV. Data quality evaluation of toxicological studies used to derive ecotoxicological benchmarks. Human and Ecological Risk Assessment, 2000, 6(5):747-765.
|
44. |
Klimisch HJ, Andreae M, Tillmann U. A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. Regul Toxicol Pharmacol, 1997, 25(1):1-5.
|
45. |
Hobbs DA, Warne MSJ, Markich SJ. Evaluation of criteria used to assess the quality of aquatic toxicity data. Integr Environ Assess Manag, 2005, 1(3):174-180.
|
46. |
STAIR (Stroke Therapy Academic Industry Roundtable). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke, 1999, 30(12):2752-2758.
|